What are the precautions for Sarilumab?

During the treatment of moderately to severely active rheumatoid arthritis(RA), patients should pay attention to the occurrence of serious infections, neutropenia, gastrointestinal perforation, immunosuppression, allergic reactions, active liver disease and liver damage, and avoid concurrent use of live vaccines during treatment.

1. Serious infections: The most common serious infections include pneumonia and cellulitis, and tuberculosis, candidiasis, and pneumocystis jiroveci have been reported among opportunistic infections. Some patients present with disseminated rather than localized disease and often take concomitant immunosuppressants such as methotrexate or corticosteroids. Although not reported in clinical studies with salivolumab, other serious infections (e.g., histoplasmosis, cryptococcosis, aspergillosis) have been reported in patients receiving other immunosuppressives for rheumatoid arthritis. Salirumab should be avoided in patients with active infections, including localized infections.

2. Neutropenia:. In clinical studies, treatment with salivolumab has been associated with reduced platelet counts; assess neutrophil counts before initiating salivolumab and monitor neutrophil counts 4 to 8 weeks after initiating treatment and every 3 months thereafter.

3. Gastrointestinal perforation: Gastrointestinal perforation has been reported in clinical studies, mainly as a complication of diverticulitis. Concurrent diverticulitis or concurrent use of NSAIDs or corticosteroids may increase the risk of gastrointestinal perforation. Physicians need to immediately evaluate patients who develop new abdominal symptoms.

4. Immunosuppression: Treatment with immunosuppressants may increase the risk of malignant tumors. The effect of salirumab treatment on the development of malignancies is unknown, but malignancies have been reported in clinical studies.

5. Hypersensitivity reactions: In controlled rheumatoid arthritis trials, 0.3% of patients reported hypersensitivity reactions requiring discontinuation of treatment. Injection site rash, rash, and hives are the most common allergic reactions. Patients are advised to seek medical attention immediately if they experience any symptoms of an allergic reaction. If you develop anaphylaxis or other allergic reactions, stop taking Salirumab immediately. Do not use sarilumab in patients with known hypersensitivity to sarilumab

6. Active liver disease and liver damage: Patients with active liver disease or liver damage are not recommended to use salirumab treatment, because salirumab treatment is associated with elevated transaminases.

7. Live vaccines: Due to the potential increased risk of infection, avoid concurrent use of live vaccines during salirumab treatment; the clinical safety of live vaccines during salirumab treatment has not been determined. There are no data on secondary transmission of infection from persons receiving live vaccines to patients receiving salirumab. The time interval between live vaccination and initiation of salirumab therapy should be consistent with current vaccination guidelines for immunosuppressants.

The patent drug Thalilutumab is a new type of drug for treating diseases. It is not yet on the market in China, and therefore it is not covered by medical insurance. The common dosage form of Salirutumab's original drug is injection, which has been marketed overseas. The price of the European version of the specification200mg*2 per box is around 17,500 (the price may fluctuate due to the exchange rate). There are currently no generic Salirutumab produced in other countries.